alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [Docket No. FDA-2022-D-1385]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice; correction.

# SUMMARY:

                        The Food and Drug Administration (FDA) is correcting a notice entitled “Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability” that appeared in the                         **Federal Register**                         of June 30, 2022. The document announced the publication of a draft guidance, the third in a series of four methodological patient-focused drug development guidance documents that describe how stakeholders (patients, researchers, medical product developers, and others) can collect and submit patient experience data and other relevant information from patients and caregivers to be used for medical product development and regulatory decision-making. The document was published with the incorrect docket number. This document corrects that error.                    

# FOR FURTHER INFORMATION CONTACT:

                        Lisa Granger, Office of Policy, Planning, Legislation and International Affairs, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115, email:                         *Lisa.Granger@fda.hhs.gov.*

# SUPPLEMENTARY INFORMATION:

                    In the                     **Federal Register**                     of Friday, June 30, 2022 (87 FR 39101), in FR Doc. 2022-13952, the following corrections are made:                

1. On page 39101, in the third column in the header of the document, “Docket No. FDA-2018-N-2455” is corrected to read “Docket No. FDA-2022-D-1385.”

2. On page 39102, in first column in “Instructions,” “Docket No. FDA-2018-N-2455” is corrected to read “Docket No. FDA-2022-D-1385.”

Dated: July 5, 2022.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2022-14677 Filed 7-8-22; 8:45 am]

BILLING CODE 4164-01-P
## F IRST 

## D ISTRICT 

## C OURT OF 

## A PPEAL 

## S TATE OF 

## F LORIDA

_____________________________
No. 1D 18

- 1816

_____________________________ A MBER J OSEPH , Appellant,

v.

J AX A NESTHESIA P ROVIDERS , LLC., a Florida P rofit C orporation
, J OHN T HOMPSON , Appe l lees

.

_____________________________

On appeal from the Circuit Court for Duval County

. Eric C. Roberson , Judge

. September 11, 2019

P ER C URIAM

.
A FFIRMED

.
L EWIS , O STERHAUS , and M.K. T HOMAS , JJ., concur

.

_____________________________ Not final until disposition of any timely and authorized motion under Fla. R. App. P. 9.330 or 9.331

.

_____________________________2 Andrew Michael Bonderud of The Bonderud Law Firm, P.A., Jacksonville ; Kristopher M. Nowicki of the Law Office of Nooney & Roberts, Jacksonville, for Appellant.

Dinah S. Stein, Aneta A. Kozub, and Mark Hicks of Hicks, Porter, Ebenfeld & Stein , P.A.
, Miami ; Tyler E. Batteese and Brendan W. Rowe of Josepher & Batteese, P.A., Tampa, for Appellee s

.
Exhibit 32.2


CERTIFICATION PURSUANT TO SECTION 906


CERTIFICATION OF CHIEF FINANCIAL OFFICER


PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)


In connection with the Quarterly Report on Form 10-Q for the period ended September 30, 2015 (the "Report") of APOLLO INVESTMENT CORPORATION (the "Registrant"), as filed with the Securities and Exchange Commission on the date hereof, I, GREGORY H. HUNT, the Chief Financial Officer of the Registrant, hereby certify, to the best of my knowledge, that:


(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and


(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.








By: /s/ Gregory W. HuntName: Gregory W. HuntDate: November 5, 2015
[Federal Register Volume 87, Number 132 (Tuesday, July 12, 2022)]
[Notices]
[Page 41347]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-14945]


=======================================================================
-----------------------------------------------------------------------

INTER-AMERICAN FOUNDATION


Sunshine Act Meetings

TIME AND DATE: August 2, 2022, ET.

PLACE: Via Zoom.

STATUS: Meeting of the Advisory Council, open to the public.

MATTERS TO BE CONSIDERED: 
[ssquf] Call to Order
[ssquf] Overview of Meeting Rules by Associate General Counsel
[ssquf] President/CEO update
[ssquf] Management Team Updates
[ssquf] Adjournment

CONTACT PERSON FOR MORE INFORMATION: Nicole Stinson, Associate General 
Counsel, (202) 683-7117.
    For Dial-in Information Contact: Nicole Stinson, Associate General 
Counsel, (202) 683-7117.
    The Inter-American Foundation is holding this meeting under the 
Government in the Sunshine Act, 5 U.S.C. 552(b).

Nicole Stinson,
Associate General Counsel.
[FR Doc. 2022-14945 Filed 7-8-22; 4:15 pm]
BILLING CODE 7025-01-P
United States Court of Appeals

for the Fifth Circuit ____________

No. 23-30154

Summary Calendar

____________

United States of America, 

Plaintiff—Appellee,

versus

Robert Lee Daniel, III, 

Defendant—Appellant.

______________________________

Appeal from the United States District Court 

for the Western District of Louisiana

USDC No. 1:22-CR-139-1

______________________________

Before Jones, Southwick, and Ho, Circuit Judges.

Per Curiam:*

The Federal Public Defender appointed to represent Robert Lee 

Daniel, III, has moved for leave to withdraw and has filed a brief in 

accordance with Anders v. California, 386 U.S. 738 (1967), and United States 

v. Flores, 632 F.3d 229 (5th Cir. 2011). Daniel has not filed a response. We 

have reviewed counsel’s brief and the relevant portions of the record 

_____________________

* This opinion is not designated for publication. See 5th Cir. R. 47.5.

United States Court of Appeals

Fifth Circuit

FILED

October 5, 2023

Lyle W. Cayce

Clerk

Case: 23-30154 Document: 00516921668 Page: 1 Date Filed: 10/05/2023
No. 23-30154

2

reflected therein. We concur with counsel’s assessment that the appeal 

presents no nonfrivolous issue for appellate review. Accordingly, counsel’s 

motion for leave to withdraw is GRANTED, counsel is excused from 

further responsibilities herein, and the appeal is DISMISSED. See 5th 

Cir. R. 42.2.

Case: 23-30154 Document: 00516921668 Page: 2 Date Filed: 10/05/2023
Exhibit 31.1



OFFICERS CERTIFICATION

PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002



I, Thomas A. Hyde, Jr., certify that:



1. I have reviewed this quarterly report on Form 10-Q of Teletouch Communications, Inc.;



2. Based on my knowledge, this report does not contain any untrue statement of
a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;



3. Based on my knowledge, the financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;



4. The registrants other certifying officer(s) and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;



(b) Evaluated the effectiveness of the registrants disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and



(c) Disclosed in this report any change in the registrants
internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial
reporting; and



5. The registrants other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent functions):



(a) All significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and



(b) Any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrants internal control over financial reporting.



|                       |  |                                            
|---------------------- |  | -------------------------------------------
|Date: January 17, 2006 |  | /s/ Thomas A. Hyde, Jr.                    
|                       |  | Thomas A. Hyde, Jr. Chief Executive Officer
IN RE C.J.H.-D.

No. COA05-939.

North Carolina Court of Appeals.

Filed June 6, 2006

Certification Date June 26, 2006

Appeal from Mecklenburg (04J288)

Case without published opinion. Affirmed.
exv10w4



 






Exhibit 10.4




Summary Compensation of Named Executive Officers




Executive Officers — Chief Operating Officers.



The Executive Committee of the Board of Directors set the base salaries and performance bonus
criteria of the Chief Operating Officers (“COOs”) in Table I for fiscal year 2005. The Compensation
Committee and the Board of Directors subsequently ratified the compensation for the COOs. For
fiscal 2005, the Executive Committee has not taken any action that would increase the salary or
bonus payable to the three COOs of the Company beyond what was approved at the beginning of the
prior fiscal year.




Table I




	 	 	 	 	 	 	 	 	 
	Name	 	Office	 	Annual Base Salary	Performance Bonus
	 	 	 	 	(Fiscal 2005)	 	Under the COO Bonus
	 	 	 	 	 	 	Plan
	Gordon D. Jones

	 	COO — West
	 	$	175,000	 	 	See Note 1
	Thomas F. Noon

	 	COO — California
	 	$	175,000	 	 	See Note 1
	George W. Seagraves

	 	COO — East
	 	$	175,000	 	 	See Note 1







	 	 	Note 1: Under the bonus plan for our COOs, Mr. Jones, Mr. Noon and Mr. Seagraves
each received a bonus payment based upon achieving certain performance goals with respect to
quarterly consolidated pre-tax income applicable to their respective operating regions.
These goals were set by the Executive Committee of the Board of Directors at the beginning
of the fiscal year and the payments were subsequently ratified by the Board.






	 	 	In addition, each of our COOs may participate in two separate deferred compensation plans.
The first plan allows the executive to make voluntary income deferrals. The second plan is a
promise by the Company to pay retirement benefits to the executive. If the executive is
employed by the Company on the last day of the current fiscal year (for example September
30, 2005), then the Company will establish a liability to him equal to 10% of his annual
base pay as of first day of the current fiscal year (for example October 1, 2004). This
liability will accrue earnings in future years at a rate established by the administrative
committee.
Exhibit
      32







**CERTIFICATION
      OF CHIEF EXECUTIVE OFFICER**


**AND
      CHIEF FINANCIAL OFFICER**


**PURSUANT
      TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**





Carol
      K.
      Nelson, Chief Executive Officer and President, and Lars H. Johnson, Chief
      Financial Officer of Cascade Financial Corporation (the "Company"), each
      certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
      906 of the Sarbanes-Oxley Act of 2002:





1.
            The
                Form 10-Q of the Company for the quarterly period ended June 30,
                2005 (the
                "Form 10-Q"), fully complies with requirements of Section 13(a) or
                15(d)
                of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d));
                and





2.
            The
                information contained in the Form 10-Q fairly presents, in all material
                respects, the financial condition and results of operations of the
                Company.





This
      certification is being furnished solely for purposes of Section 906 and is
      not
      being filed as part of this quarterly report.








Date:
      August 5, 2005




/s/
      Carol K.
      Nelson


Carol
      K.
      Nelson, President and CEO







/s/
      Lars H. Johnson


Lars
      H.
      Johnson, Chief Financial Officer
# L_2012144EN.01001501.xml

| 5.6.2012 | EN | Official Journal of the European Union | L 144/15 |
| --- | --- | --- | --- |

5.6.2012

EN

Official Journal of the European Union

L 144/15

---

COMMISSION IMPLEMENTING REGULATION (EU) No 469/2012

of 1 June 2012

correcting Implementing Regulation (EU) No 69/2012 on the issue of licences for importing rice under the tariff quotas opened for the January 2012 subperiod by Implementing Regulation (EU) No 1273/2011

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Council Regulation (EC) No 1234/2007 of 22 October 2007 establishing a common organisation of agricultural markets and on specific provisions for certain agricultural products (Single CMO Regulation) (1),

Having regard to Commission Implementing Regulation (EU) No 1273/2011 of 7 December 2011 opening and providing for the administration of certain tariff quotas for imports of rice and broken rice (2), and in particular the first paragraph of Article 5 thereof,

Whereas:

| (1) | A check has revealed an error in the Annex to Commission Implementing Regulation (EU) No 69/2012 (3) regarding the quantity available for the July 2012 subperiod for the quota of broken rice falling within CN Code 1006 40 00 provided for in Article 1(1)(c) of Implementing Regulation (EU) No 1273/2011 and with order number 09.4149. |
| --- | --- |

(1)

A check has revealed an error in the Annex to Commission Implementing Regulation (EU) No 69/2012 (3) regarding the quantity available for the July 2012 subperiod for the quota of broken rice falling within CN Code 1006 40 00 provided for in Article 1(1)(c) of Implementing Regulation (EU) No 1273/2011 and with order number 09.4149.

| (2) | Implementing Regulation (EU) No 69/2012 should therefore be corrected accordingly. |
| --- | --- |

(2)

Implementing Regulation (EU) No 69/2012 should therefore be corrected accordingly.

| (3) | In order to ensure sound management of the procedure for issuing import licences, this Regulation should enter into force immediately after its publication, |
| --- | --- |

(3)

In order to ensure sound management of the procedure for issuing import licences, this Regulation should enter into force immediately after its publication,

HAS ADOPTED THIS REGULATION:

Article 1

In point (c) of the Annex to Implementing Regulation (EU) No 69/2012, ‧Quota of broken rice covered by CN code 1006 40 00 as provided for in Article 1(1)(c) of Implementing Regulation (EU) No 1273/2011‧, in the line concerning the quota with order number 09.4149, the quantity ‧44 047 269‧ shall be replaced by the quantity ‧44 921 269‧.

Article 2

This Regulation shall enter into force on the day of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 1 June 2012.

For the Commission, On behalf of the President,

José Manuel SILVA RODRÍGUEZ

Director-General for Agriculture and Rural Development

---

(1)  
  OJ L 299, 16.11.2007, p. 1.

1

(2)  
  OJ L 325, 8.12.2011, p. 6.

2

(3)  
  OJ L 24, 27.1.2012, p. 7.

3

---
**EXHIBIT 31.1**
 
 **CERTIFICATION PURSUANT TO**
 **SECTION 302 OF THE**
 **SARBANES-OXLEY ACT OF 2002**
 
 **CERTIFICATIONS**
 
 I, Todd M. Raba, certify that:
 
 1.

I have reviewed this quarterly report on Form 10-Q ofMidAmerican Energy Company;2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.

The registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)
Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andc)
Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and5.

The registrants other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent function):a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; andb)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. 
 
 
 Date: November 4, 2004
 /s/ Todd M. Raba
 Todd M. Raba
 President
 (chief executive officer)
IIB 

110TH CONGRESS 

2D SESSION H. R. 5736 

IN THE SENATE OF THE UNITED STATES 

SEPTEMBER 22 (legislative day, SEPTEMBER 17), 2008 

Received 

OCTOBER 2 (legislative day, SEPTEMBER 17), 2008 

Read twice and referred to the Committee on Veterans’ Affairs 

AN ACT 

To designate the Department of Veterans Affairs outpatient 

clinic in Gadsden, Alabama, as the Colonel Ola Lee Mize 

Veterans Clinic. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


wwoods2 on PRODPC68 with BILLS
2 

HR 5736 RFS

1 SECTION 1. FINDING. 

2 Congress finds that Colonel Ola Lee Mize, a Medal 

3 of Honor recipient, is a highly decorated veteran from the 

4 State of Alabama. 

5 SEC. 2. DESIGNATION OF DEPARTMENT OF VETERANS AF6 FAIRS OUTPATIENT CLINIC IN GADSDEN, 

7 ALABAMA. 

8 The Department of Veterans Affairs community 

9 based outpatient clinic in Gadsden, Alabama, shall be 

10 known and designated as the ‘‘Colonel Ola Lee Mize Vet11 erans Clinic’’. Any reference to such community based out12 patient clinic in any law, regulation, map, document, 

13 record, or other paper of the United States shall be consid14 ered to be a reference to the Colonel Ola Lee Mize Vet15 erans Clinic. 

Passed the House of Representatives September 17, 

2008. 

Attest: LORRAINE C. MILLER, 

Clerk. 


wwoods2 on PRODPC68 with BILLS